PaxVax Lands $22,000,000 Series B Funding Round

  • Feed Type
  • Date
    12/5/2013
  • Company Name
    PaxVax
  • Mailing Address
    3985A Sorrento Valley Boulevard San Diego, CA 92121
  • Company Description
    PaxVax is a privately held, fully integrated vaccine company, based in Menlo Park, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact.
  • Website
    http://www.paxvax.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company intends to use the capital to continue to fund the recently initiated Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal international program, which is comprised of cholera challenge, safety, and immunogenicity studies.
  • M&A Terms
  • Venture Investor
    Ignition Capital
  • Venture Investor
    Blue Haven Initiative
  • Venture Investor
    Ignition Partners

Trending on Xconomy